NAG
CRSP icon

Northstar Advisory Group’s CRISPR Therapeutics CRSP Stock Holding History

Northstar Advisory Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,495
Closed -$503K – 101
2021
Q3 		$503K Buy
+4,495
New +$565K 0.49% 34

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Northstar Advisory Group's CRSP Position: Q4 2021 in Review

Northstar Advisory Group sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 4,495 shares — an estimated $503K sold.

Northstar Advisory Group first reported a position in CRSP in Q3 2021 and held it in 1 quarter. The position peaked at $503K in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Northstar Advisory Group reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Northstar Advisory Group sold 4,495 CRISPR Therapeutics shares in Q4 2021, an estimated $503K.
  • Northstar Advisory Group first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 1 quarter.
  • Northstar Advisory Group's CRISPR Therapeutics position peaked at $503K in Q3 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Northstar Advisory Group's 13F filing for Q4 2021, filed 20 Jan 2022.